2.92
+0.03(+1.04%)
Currency In USD
Previous Close | 2.89 |
Open | 2.88 |
Day High | 2.93 |
Day Low | 2.88 |
52-Week High | 7.56 |
52-Week Low | 2.67 |
Volume | 5,035 |
Average Volume | 19,639 |
Market Cap | 25.84M |
PE | -6.08 |
EPS | -0.48 |
Moving Average 50 Days | 2.92 |
Moving Average 200 Days | 3.26 |
Change | 0.03 |
If you invested $1000 in Daré Bioscience, Inc. (DARE) 10 years ago, it would be worth $3.97 as of May 19, 2025 at a share price of $2.92. Whereas If you bought $1000 worth of Daré Bioscience, Inc. (DARE) shares 5 years ago, it would be worth $227.41 as of May 19, 2025 at a share price of $2.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025
GlobeNewswire Inc.
May 06, 2025 12:00 PM GMT
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.
Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategyDaré recently announced its new dual-path approach for its proprietary Sildenafil Cream formulation and is targeting availability via
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year
GlobeNewswire Inc.
Apr 07, 2025 12:00 PM GMT
Daré unveiled its new dual-path approach for its proprietary Sildenafil Cream formulation after urging on the part of the healthcare community and hearing the demand from womenDaré is targeting availability of its proprietary Sildenafil Cream formula